ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

41.20
-1.00
(-2.37%)
Closed December 09 4:00PM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.20
Bid
40.80
Ask
42.00
Volume
978
39.60 Day's Range 42.80
21.40 52 Week Range 58.50
Previous Close
42.20
Open
42.80
Last Trade
40
@
41.2
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.8-10.4347826087464739.624844.22983871DE
4-10.3-2051.551.539.612544.72627361DE
12-4-8.8495575221245.251.539.612747.17167127DE
26-7.8-15.91836734694957.539.615948.54794972DE
5219.287.27272727272258.521.39999917544.36210739DE
15617.473.109243697523.858.51916742.00023485DE
26017.473.109243697523.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NL8Genesis Ai Corp
0.035 €
(130.26%)
78.41k
C0MCCS Abwicklungs AG
0.30 €
(114.29%)
125.51k
2WOWide Open Agriculture Ltd
0.013 €
(85.71%)
35.39k
1UR1Bee Vectoring Technologies International Inc
0.0075 €
(50.00%)
261.4k
KEHChinese People Holdings Co Ltd
0.0045 €
(50.00%)
22.92k
Y7GBioAge Labs Inc
4.46 €
(-76.53%)
20.69k
4APApollo Minerals Ltd
0.005 €
(-41.18%)
49.2k
HF2Reflex Advanced Materials Corp
0.0136 €
(-38.18%)
11.9k
R1EAEV Resources Ltd
0.001 €
(-37.50%)
230.95k
NJF1Grid Metals Corp
0.016 €
(-37.25%)
2k
AXIAtos SE
0.0027 €
(-3.57%)
926.53M
D7GNel ASA
0.2699 €
(2.82%)
5.14M
3CPXiaomi Corporation
3.91 €
(8.34%)
4.02M
9SBSOL Global Investments Corp
0.28 €
(16.67%)
4M
POQ88 Energy Limited
0.001 €
(-16.67%)
2.87M

Discussion

View Full Feed
TRAPPER JIM TRAPPER JIM 3 minutes ago
Thanks. I just have to find the time to work on my truck and fix it. 
cadillacdave cadillacdave 3 minutes ago
It seems like Thom operates from the theory that no news is good news. However, most of the investors here would disagree.
WDDD
TenKay TenKay 3 minutes ago
LOL…sure…
HMBL
ge11 ge11 4 minutes ago
https://www.voanews.com/a/china-may-use-rare-earth-to-retaliate-against-us-say-analysts/7892877.html
NB
BigJuan BigJuan 4 minutes ago
Agreed no metro trains allowed..... lol
GMPR
Iggy_Bot Iggy_Bot 4 minutes ago
And a green close is a good close.
GVSI
XMaster2023 XMaster2023 4 minutes ago
Just because you’re paid by the post doesn’t mean the longs are.
NWBO
TenKay TenKay 5 minutes ago
TSNP was one of the great OTC runs. No question. But that simply isn’t going to happen again…as much as some might like it to.

Foote’s family and friends made over $50 million on it.

I was wondering when he would talk away.
HMBL
Stock_Barber Stock_Barber 5 minutes ago
30,600 shares is "alot"? Seriously?

alot of selling going on for tax write off
JNSH
vischers vischers 5 minutes ago
News coming
SWRM
thegoodnessparadox thegoodnessparadox 5 minutes ago
No two ways around it, consolidation appears to be required. It is what I have been saying; they are inextricably linked.
GNCP
getmoreshares getmoreshares 5 minutes ago
1-Z (Exit report)
GMZP
GREGG THE GREEK GREGG THE GREEK 6 minutes ago
Took a block here today.


A trusted friend of mine alerted me to the volume and I decided to hop on the train.


Hopefully a bullet train and not Chicago Metro lol


GMPR
GMPR
DewDiligence DewDiligence 6 minutes ago
LLY authorizes new $15B buyback—raises dividend:

https://finance.yahoo.com/news/lilly-announces-15-billion-share-211600555.html

The new $15B authorization is in addition to the prior $5B buyback that was exhausted during the current quarter.

The BoD didn'
LLY
getmoreshares getmoreshares 6 minutes ago
https://www.sec.gov/edgar/search/#/ciks=0001973160&entityName=GEMZ%2520Corp.%2520NV%2520(GMZP)%2520(CIK%25200001973160)
GMZP
DrSleep DrSleep 6 minutes ago
Anyone know why my post got deleted? Did one of the ELTP haters take it down?
ELTP
glenn1919 glenn1919 6 minutes ago
CPIX................................https://stockcharts.com/h-sc/ui?s=CPIX&p=W&b=5&g=0&id=p86431144783
CPIX
DAR53 DAR53 7 minutes ago
NS, thanks for the clarification. I knew they had referenced their G same as V.
Thanks for all you do to support AMRN on this board.
AMRN
Techroemancer Techroemancer 7 minutes ago
I think I saw Shoondale in the video from today 🤣
MWWC
Curt D Curt D 8 minutes ago
That is sound logic in my book.
RDAR
JMoneyHoops JMoneyHoops 8 minutes ago
https://x.com/jmoney_hoops/status/1866234144076058903?s=46&t=EuLw-SVIgNfV5yGP5vc4tQ
TLSS
hedge_fun hedge_fun 8 minutes ago
The OTC (Over-the-Counter) Expert Market is a market tier for companies that are unable or unwilling to provide public disclosure:
*They don't make current information available through OTC Markets' disclosure and news service
*The information they do provide is older than six months
APRU
Hikerbc Hikerbc 8 minutes ago
I hope you all are correct, holding for 4 years, and then adding last few months here. Would welcome some positive action, which will not be flattened by shorting from the hedge funds.
AMC
KingRichard3rd KingRichard3rd 8 minutes ago
Nope, I didn't.
I'll try to get AH tomorrow morning.
AMC

Your Recent History

Delayed Upgrade Clock